Microarray analysis of peripheral blood lymphocytes transcriptome in breast cancer patients

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Breast cancer is number one in terms of indicators of mortality and morbidity in women. In postgenomicera it was revealed that pathology development is linked with specificities of gene expression including transcriptional, posttransctiptional, translational, epigenetical regulation. In research was included biomaterial of 16 patients (8 patients with I/ IIstage luminal A breast cancer and 8 healthy women). Functional enrichment analysis using WebGestalt source and different databases (Gene Ontology, KEGG) showed alterations in expression of genes involved in immunological response, metabolism of carbohydrates, glutathione and nicotinamide, DNA repair, ion transport and intracellular signals transition. Obtained results expand our vision about specificities of blood mononuclears transcriptome during breast cancer on early stage.

全文:

受限制的访问

作者简介

V. Minina

Federal Research Centre of Coal and Coal Chemistry, Siberian Branch of the Russian Academy of Sciences; Kemerovo State University

Email: vladislasbus2358@yandex.ru
俄罗斯联邦, Kemerovo, 650000; Kemerovo, 650000

R. Titov

Federal Research Centre of Coal and Coal Chemistry, Siberian Branch of the Russian Academy of Sciences; Kemerovo State University

Email: vladislasbus2358@yandex.ru
俄罗斯联邦, Kemerovo, 650000; Kemerovo, 650000

V. Buslaev

Federal Research Centre of Coal and Coal Chemistry, Siberian Branch of the Russian Academy of Sciences

编辑信件的主要联系方式.
Email: vladislasbus2358@yandex.ru
俄罗斯联邦, Kemerovo, 650000

R. Savchenko

Tomsk National Research Medical Centre, Russian Academy of Sciences

Email: vladislasbus2358@yandex.ru

Scientific Research Institute of Medical Genetics

俄罗斯联邦, Tomsk, 634050

A. Slepcov

Tomsk National Research Medical Centre, Russian Academy of Sciences

Email: vladislasbus2358@yandex.ru

Scientific Research Institute of Medical Genetics

俄罗斯联邦, Tomsk, 634050

M. Bakanova

Federal Research Centre of Coal and Coal Chemistry, Siberian Branch of the Russian Academy of Sciences; Kemerovo State Medical University

Email: vladislasbus2358@yandex.ru
俄罗斯联邦, Kemerovo, 650000; Kemerovo, 650000

N. Gavrineva

Kemerovo State University

Email: vladislasbus2358@yandex.ru
俄罗斯联邦, Kemerovo, 650000

M. Katanakhova

Federal Research Centre of Coal and Coal Chemistry, Siberian Branch of the Russian Academy of Sciences

Email: vladislasbus2358@yandex.ru
俄罗斯联邦, Kemerovo, 650000

A. Glushkov

Federal Research Centre of Coal and Coal Chemistry, Siberian Branch of the Russian Academy of Sciences

Email: vladislasbus2358@yandex.ru
俄罗斯联邦, Kemerovo, 650000

参考

  1. Obeagu E.I., Obeagu G.U. Breast cancer: A review of risk factors and diagnosis // Medicine. 2024. V. 103. № 3. P. 1–6. https://doi.org/10.1097/MD.0000000000036905
  2. Sun Y.S., Zhao Z., Yang Z.N. et al. Risk factors and preventions of breast cancer // Int. J. Biol. Sci. 2017. V. 13. № 11. P. 1387–1397. https://doi.org/10.7150/ijbs.21635
  3. Ignatiadis M., Sotiriou C. Luminal breast cancer: From biology to treatment // Nat. Rev. Clin. Oncol. 2013. V. 10. № 9. P. 494–506. https://doi.org/10.1038/nrclinonc.2013.124
  4. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours // Nature. 2012. V. 490. № 7418. P. 61–70. https://doi.org/10.1038/nature11412
  5. Turner K.M., Yeo S.K., Holm T.M. et al. Heterogeneity within molecular subtypes of breast cancer // Am. J. Physiol. Cell Physiol. 2021. V. 321. № 2. P. 343–354. https://doi.org/10.1152/ajpcell.00109.2021
  6. Markou A., Tzanikou E., Lianidou E. The potential of liquid biopsy in the management of cancer patients // Seminars in Cancer Biology. 2022. V. 84. P. 69–79. https://doi.org/10.1016/j.semcancer.2022.03.013
  7. Li J., Guan X., Fan Z. et al. Non-invasive biomarkers for early detection of breast cancer // Cancers. 2020. V. 12. № 10. P. 2767–2795. https://doi.org/10.3390/cancers12102767
  8. Balacescu O., Balacescu L., Virtic O. et al. Blood Genome-wide transcriptional profiles of HER2 negative breast cancers patients // Mediators Inflamm. V. 2016. № 2016. https://doi.org/10.1155/2016/3239167
  9. Čelešnik H., Potočnik U. Peripheral blood transcriptome in breast cancer patients as a source of less invasive immune biomarkers for personalized medicine, and implications for triple negative breast cancer // Cancers (Basel). 2022. V. 14. № 3. P. 591–612. https://doi.org/10.3390/cancers14030591
  10. Jiang Y.Z., Ma D., Suo C. et al. Genomic and transcriptomic landscape of triple-negative breast cancers: Subtypes and treatment strategies // Cancer Cell. 2019. V. 35. № 3. P. 428–440. https://doi.org/10.1016/j.ccell.2019.02.001
  11. Chen Q., Liu Y., Gao Y. et al. A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers // Sci. Data. 2022. V. 9. № 1. P. 587–598. https://doi.org/10.1038/s41597-022-01681-z
  12. Mares-Quiñones M.D., Galán-Vásquez E., Pérez-Rueda E. et al. Identification of modules and key genes associated with breast cancer subtypes through network analysis // Sci. Rep. 2024. V. 14. № 1. P. 12350–12368. https://doi.org/10.1038/s41598-024-61908-4
  13. Wang C., Lv X., Meng N. et al. Accurate prognosis of patients with luminal type A and HER-2 overexpressing breast cancer via the partitioning calculation method of the Ki-67 index // World Acad. Sci. J. 2023. V. 5. № 4. P. 21–30. https://doi.org/10.3892/wasj.2023.198
  14. Минина В.И., Дружинин В.Г., Ларионов А.В. и др. Микроматричный анализ транскриптома мононуклеаров периферической крови у больных раком легкого // Генетика. 2022. Т. 58. № 7. С. 798–807. https://doi.org/10.31857/S0016675822070128
  15. Sharma P., Sahni N.S., Tibshirani R. et al. Early detection of breast cancer based on gene-expression patterns in peripheral blood cells // Breast Cancer Res. 2005. V. 7. № 5. P. 634–644. https://doi.org/10.1186/bcr1203
  16. Aarøe J., Lindahl T., Dumeaux V. et al. Gene expression profiling of peripheral blood cells for early detection of breast cancer // Breast Cancer Res. 2010. V. 12. № 1. P. 1–11. https://doi.org/10.1186/bcr2472
  17. Zuckerman N.S., Yu H., Simons D.L. et al. Altered local and systemic immune profiles underlie lymph node metastasis in breast cancer patients // Int. J. of Cancer. 2013. V. 132. № 11. P. 2537–2547. https://doi.org/10.1002/ijc.27933
  18. Whiteside T.L. Regulatory T cells ubsetsin human cancer: Are the regulating for oragains t tumorp rogression? // Cancer Immunol., Immunotherapy. 2014. V. 63. № 1. P. 67–72. https://doi.org/10.1007/s00262-013-1490-y
  19. Han X., Han B., Luo H. et al. Integrated multi-omics profiling of young breast cancer patients reveals a correlation between galactose metabolism pathway and poor disease-free survival // Cancers. 2023. V. 15. № 18. P. 4637–4650. https://doi.org/10.3390/cancers15184637
  20. Xu S., Feng Y., Zhao S. Proteins with evolutionarily hypervariable domains are associated with immune response and better survival of basal-like breast cancer patients // Computational and Struct. Biotechnol. J. 2019. V. 17. P. 430–440. https://doi.org/10.1016/j.csbj.2019.03.008
  21. Pangeni R.P., Channathodiyil P., Huen D.S. et al. The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain // Clin. Epigenet. 2015. V. 7. № 1. P. 57–72. https://doi.org/10.1186/s13148-015-0089-x
  22. Song K.H., Park M.S., Nandu T.S. et al. GALNT14 promotes lung-specific breast cancer metastasis by modulating self-renewal and interaction with the lung microenvironment // Nat. Commun. 2016. V. 7. № 1. P. 13796–13811. https://doi.org/10.1038/ncomms13796
  23. Lien E.C., Lyssiotis C.A., Juvekar A. et al. Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer // Nat. Cell. Biol. 2016. V. 18. № 5. P. 572–578. https://doi.org/10.1038/ncb3341
  24. Zhao C., Zhang T., Xue S. et al. Adipocyte-derived glutathione promotes obesity-related breast cancer by regulating the SCARB2–ARF1–mTORC1 complex // Cell Metabolism. 2024. V. 1550. № 24. P. 00395–00399. https://doi.org/10.1016/j.cmet.2024.09.013
  25. Mehta V., Suman P., Chander H. High levels of unfolded protein response component CHAC1 associates with cancer progression signatures in malignant breast cancer tissues // Clin. Transl. Oncol. 2022. V. 24. № 12. P. 2351–2365. https://doi.org/10.1007/s12094-022-02889-6
  26. Lou W., Ding B., Wang S., Fu P. Overexpression of GPX3, a potential biomarker for diagnosis and prognosis of breast cancer, inhibits progression of breast cancer cells in vitro // Cancer Cell Int. 2020. V. 20. № 1. P. 378–393. https://doi.org/10.1186/s12935-020-01466-7
  27. Shen H., Huo R., Zhang Y., et al. A Pilot Study to assess the suitability of riboflavin as a surrogate marker of breast cancer resistance protein in healthy participants // J. Pharmacol. Exp. Theor. 2024. V. 390. № 2. P. 162–173. https://doi.org/10.1124/jpet.123.002015
  28. Wang S., Böhnert V., Joseph A.J. et al. ENPP1 is an innate immune checkpoint of the anticancer cGAMP–STING pathway in breast cancer // Proc. Natl Acad. Sci. USA. 2023. V. 120. № 52. P. 1–12. https://doi.org/10.1073/pnas.2313693120
  29. Amens J.N., Bahçecioglu G., Zorlutuna P. Immune system effects on breast cancer // Cell Mol. Bioeng. 2021. V. 14. № 4. P. 279–292. https://doi.org/10.1007/s12195-021-00679-8
  30. Lin C.Y., Beattie A., Baradaran B. et al. Contradictory mRNA and protein misexpression of EEF1A1 in ductal breast carcinoma due to cell cycle regulation and cellular stress // Sci. Rep. 2018. V. 8. № 1. P. 13904–13916. https://doi.org/10.1038/s41598-018-32272-x
  31. Jin H., Kim H.J. NLRC4, ASC and caspase-1 are inflammasome components that are mediated by P2Y2R activation in breast cancer cells // IJMS. 2020. V. 21. № 9. P. 3337–3352. https://doi.org/10.3390/ijms21093337
  32. Li X., Poire A., Jeong K.J. et al. C5aR1 inhibition reprograms tumor associated macrophages and reverses PARP inhibitor resistance in breast cancer // Nat. Commun. 2024. V. 15. № 1. P. 4485–4505. https://doi.org/10.1038/s41467-024-48637-y
  33. Zou J., Chen Y., Ji Z. et al. Identification of C4BPA as biomarker associated with immune infiltration and prognosis in breast cancer // Transl. Cancer Res. 2024. V. 13. № 1. P. 25–45. https://doi.org/10.21037/tcr-23-1215
  34. Kim M., Choi H.Y., Woo J.W. et al. Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast // Sci. Rep. 2021. V. 11. № 1. P. 18007–18019. https://doi.org/10.1038/s41598-021-97390-5
  35. Cui H., Ren X., Dai L. et al. Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer // Front. Immunol. 2023. V. 14. P. 1145552–1145569. https://doi.org/10.3389/fimmu.2023.1145552
  36. Michaels A.M., Zoccarato A., Hoare Z. et al. Disrupting Na+ ion homeostasis and Na+/K+ ATPase activity in breast cancer cells directly modulates glycolysis in vitro and in vivo // Cancer Metab. 2024. V. 12. № 1. P. 15–31. https://doi.org/10.1186/s40170-024-00343-5
  37. Chen J., Liu X., Huang H. et al. High salt diet may promote progression of breast tumor through eliciting immune response // Int. Immunopharmacology. 2020. V. 87. https://doi.org/10.1016/j.intimp.2020.106816
  38. Zhang M., Zhang Z., Tian X., et al. NEDD4L in human tumors: Regulatory mechanisms and dual effects on anti-tumor and pro-tumor // Front. Pharmacol. 2023. V. 14. https://doi.org/10.3389/fphar.2023.1291773
  39. Hwang K.T., Chung J.K., Jung I.M., et al. COL18A1 as the candidate gene for the prognostic marker of breast cancer according to the analysis of the DNA copy number variation by array CGH // J. Breast Cancer. 2010. V. 13. № 1. P. 37–46. https://doi.org/10.4048/jbc.2010.13.1.37
  40. Ding J., Li C., Shu K. et al. Membrane metalloendopeptidase (MME) is positively correlated with systemic lupus erythematosus and may inhibit the occurrence of breast cancer // PLoS One. 2023. V. 18. № 8. P. 1–15. https://doi.org/10.1371/journal.pone.0289960
  41. Levine K.M., Ding K., Chen L., Oesterreich S. FGFR4: A promising therapeutic target for breast cancer and other solid tumors // Pharmacology & Therapeutics. 2020. V. 214. https://doi.org/10.1016/j.pharmthera.2020.107590
  42. Teo W.S., Nair R., Swarbrick A. New insights into the role of ID proteins in breast cancer metastasis: A MET affair // Breast Cancer Res. 2014. V. 16. № 2. P. 305–307. https://doi.org/10.1186/bcr3654
  43. Liang J., Pan Y., Zhang W. et al. Associations of age at diagnosis of breast cancer with incident myocardial infarction and heart failure: A prospective cohort study // eLife. 2024. V. 13. P. 1–13. https://doi.org/10.7554/eLife.95901
  44. Li S., Hu J., Li G. et al. Epigenetic regulation of LINC01270 in breast cancer progression by mediating LAMA2 promoter methylation and MAPK signaling pathway // Cell Biol. Toxicol. 2023. V. 39. № 4. P. 1359–1375. https://doi.org/10.1007/s10565-022-09763-9
  45. Zhang J., Dai H., Huo L. et al. Cytosolic DNA accumulation promotes breast cancer immunogenicity via a STING-independent pathway // J. Immunother. Cancer. 2023. V. 11. № 10. P. 1–14. https://doi.org/10.1136/jitc-2023-007560
  46. Oskarsson T. Extracellular matrix components in breast cancer progression and metastasis // The Breast. 2013. V. 22. P. 66–72. https://doi.org/10.1016/j.breast.2013.07.012
  47. Singh N., Chakraborty R., Bhullar R.P., Chelikani P. Differential expression of bitter taste receptors in non-cancerous breast epithelial and breast cancer cells // Biochem. Biophys. Res. Communications. 2014. V. 446. № 2. P. 499–503. https://doi.org/10.1016/j.bbrc.2014.02.140
  48. McCart Reed A.E., Song S., Kutasovic J.R. et al. Thrombospondin-4 expression is activated during the stromal response to invasive breast cancer // Virchows Arch. 2013. V. 463. № 4. P. 535–545. https://doi.org/10.1007/s00428-013-1468-3
  49. Fan J., Zhang Z., Chen H. et al. Zinc finger protein 831 promotes apoptosis and enhances chemosensitivity in breast cancer by acting as a novel transcriptional repressor targeting the STAT3/Bcl2 signaling pathway // Genes & Diseases. 2024. V. 11. № 1. P. 430–448. https://doi.org/10.1016/j.gendis.2022.11.023
  50. Lei T., Zhang W., He Y. et al. ZNF276 promotes the malignant phenotype of breast carcinoma by activating the CYP1B1-mediated Wnt/β-catenin pathway // Cell Death Dis. 2022. V. 13. № 9. P. 781–796. https://doi.org/10.1038/s41419-022-05223-8

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Protein network for overexpressed genes based on the TCGARefseq (BRCA) database.

下载 (219KB)
索引源数据
3. Fig. 2. Protein network for downregulated genes based on the TCGARefseq (BRCA) database.

下载 (211KB)
索引源数据

版权所有 © Russian Academy of Sciences, 2025